"name","uuid:ID","id","label","description","rationale","instanceType"
"Study Design 1","73c91a51-02c7-42af-ab47-2caebc34dd03","StudyDesign_1","","The main design for the study","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyDesign"
